



Original Research

Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma



Oliver J. Kennedy^{a,*,1}, Michal Kicinski^{b,1}, Sara Valpione^c, Sara Gandini^d, Stefan Suciu^b, Christian U. Blank^e, Georgina V. Long^f, Victoria G. Atkinson^g, Stéphane Dalle^h, Andrew M. Haydonⁱ, Andrey Meshcheryakov^j, Adnan Khattak^k, Matteo S. Carlino^l, Shahneen Sandhu^m, James Larkinⁿ, Susana Puig^o, Paolo A. Ascierto^p, Piotr Rutkowski^q, Dirk Schadendorf^r, Rutger Koornstra^s, Leonel Hernandez-Aya^t, Anna M. Di Giacomo^u, Alfonsus J.M. van den Eertwegh^v, Jean-Jacques Grob^w, Ralf Gutzmer^x, Rahima Jamal^y, Alexander C.J. van Akkooi^e, Caroline Robert^z, Alexander M.M. Eggermont^{aa,ab}, Paul Lorigan^{ac}, Mario Mandala^{ad}

^a University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom

^b EORTC Headquarters, Brussels, Belgium

^c Cancer Research UK Manchester Institute, Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom

^d Molecular and Pharmaco-Epidemiology Unit, European Institute of Oncology, IRCCS, Milano, Italy

^e Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands

^f Melanoma Institute Australia, The University of Sydney, And Mater and Royal North Shore Hospitals, Sydney, NSW, Australia

^g Princess Alexandra Hospital, Brisbane, QLD, Australia

^h Hospices Civils de Lyon Cancer Institute, Lyon, France

ⁱ Alfred Hospital, Melbourne, VIC, Australia

^j NN Blokhin Cancer Research Center, Moscow, Russian Federation

^k Fiona Stanley Hospital & Edith Cowan University, Perth, WA, Australia

^l Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney, Sydney, NSW, Australia

^m Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

ⁿ Royal Marsden Hospital, London, United Kingdom

^o Hospital Clinic de Barcelona, Universitat de Barcelona, Spain & Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain

^p Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy

* Corresponding author:

E-mail address: ojk@doctors.org.uk (O.J. Kennedy).

¹ Contributed equally to this paper.

^q Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

^r University Hospital Essen, Essen and German Cancer Consortium, Heidelberg, Germany

^s Radboud University Medical Center Nijmegen, Nijmegen, Netherlands

^t Washington University School of Medicine, St. Louis, MO, USA

^u Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy

^v Amsterdam University Medical Center, Location VUMC, Amsterdam, Netherlands

^w Aix Marseille University, Hôpital de la Timone, Marseille, France

^x Skin Cancer Center, Hannover Medical School, Hannover, and Department of Dermatology, Johannes Wesling Klinikum Minden, Ruhr University Bochum, Minden, Germany

^y Centre Hospitalier de l'Université de Montréal (CHUM), Centre de recherche du CHUM, Montreal, QC, Canada

^z Gustave Roussy and Paris-Saclay University, Villejuif, France

^{aa} Comprehensive Cancer Center Munich, Munich, Germany

^{ab} Princess Máxima Center and University Medical Center Utrecht, Utrecht, Netherlands

^{ac} Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, United Kingdom

^{ad} University of Perugia, Santa Maria Misericordia Hospital, Perugia, Italy

Received 28 January 2022; accepted 28 January 2022

Available online 24 February 2022

KEYWORDS

Melanoma;
Immunotherapy;
Beta-blockers;
Immunomodulation;
Adrenergic beta-
antagonists

Abstract Background: β -adrenergic receptors are upregulated in melanoma cells and contribute to an immunosuppressive, pro-tumorigenic microenvironment. This study investigated the prognostic and predictive value of β -adrenoreceptor blockade by β -blockers in the EORTC1325/KEYNOTE-054 randomised controlled trial.

Methods: Patients with resected stage IIIA, IIIB or IIIC melanoma and regional lymphadenectomy received 200 mg of adjuvant pembrolizumab ($n = 514$) or placebo ($n = 505$) every three weeks for one year or until recurrence or unacceptable toxicity. At a median follow-up of 3 years, pembrolizumab prolonged recurrence-free survival (RFS) compared to placebo (hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.47–0.68). β -blocker use was defined as oral administration of any β -blocker within 30 days of randomisation. A multivariable Cox proportional hazard model was used to estimate the HR for the association between the use of β -blockers and RFS.

Results: Ninety-nine (10%) of 1019 randomised patients used β -blockers at baseline. β -blockers had no independent prognostic effect on RFS: HR 0.96 (95% CI 0.70–1.31). The HRs of RFS associated with β -blocker use were 0.67 (95% CI 0.38–1.19) in the pembrolizumab arm and 1.15 (95% CI 0.80–1.66) in the placebo arm. The HR of RFS associated with pembrolizumab compared to placebo was 0.34 (95% CI 0.18–0.65) among β -blocker users and 0.59 (95% CI 0.48–0.71) among those not using β -blockers.

Conclusions: This study suggests no prognostic effect of β -blockers in resected high-risk stage III melanoma. However, β -blockers may predict improved efficacy of adjuvant pembrolizumab treatment. The combination of immunotherapy with β -blockers merits further investigation.

This study is registered with [ClinicalTrials.gov](https://clinicaltrials.gov), NCT02362594, and EudraCT, 2014-004944-37.

© 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

In vitro studies have demonstrated that expression of β -adrenoreceptors is up-regulated in a diverse range of cancers. β -adrenergic receptor activation contributes to a pro-tumorigenic microenvironment through its roles in apoptosis, inflammation, angiogenesis, DNA repair and cellular immunity [1,2]. Among the 29 most common human cancers, melanoma most strongly expresses β -adrenoreceptors, including the individual receptor subtypes β 1, β 2 and β 3 [3,4]. All three subtypes are

thought to play a role in melanoma development and progression through promoting the release of pro-tumorigenic cytokines and metalloproteases and reducing T-cell expansion and cytotoxicity [1,3].

β -blockers are a well-tolerated and frequently prescribed class of medication with a range of indications. They are subclassified as either β 1-selective β -blockers or non-selective, which target β 1, β 2 and, in some cases, β 3 receptors. Population-based studies have suggested that concomitant use of β -blockers has a beneficial effect on clinical outcomes in certain cancers.

The strongest evidence of a beneficial effect is in melanoma [5–7], though most studies have been conducted with poorly defined cases identified from cancer registers and of various stages and unspecified treatments.

A separate but related area of interest is the predictive effect of β -blockers use on immunotherapy efficacy. Immunotherapy has transformed the treatment of melanoma and is now a standard of care both in the metastatic setting and as adjuvant therapy for resected stage III disease [8–11]. Preclinical studies have demonstrated that programmed cell death protein 1 (PD-1) inhibitors are more effective in mice when combined with pharmacological β -blockade [12]. A retrospective clinical study in the United States involving 195 patients with metastatic melanoma treated with one or a combination of anti-PD-1, anti-CTLA-4 and IL-2 immunotherapy agents found improved overall survival (numerical estimates not reported) among patients using non-selective β -blockers [13].

This study aimed to further investigate the prognostic and predictive value of β -blockers in the European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma [9–11].

2. Patients and methods

2.1. Study population

A retrospective analysis of patients enrolled in the EORTC 1325 trial was conducted, which compared adjuvant pembrolizumab to placebo among patients aged 18 years or older, with biopsy confirmed high-risk stage IIIA (minimum sentinel node tumour deposit >1 mm), IIIB or IIIC melanoma and complete regional lymphadenectomy within 13 weeks prior to starting treatment. Recruitment was between August 2015 and November 2016 across 123 centres in 23 countries. Patients were excluded if they had an Eastern Cooperative Oncology Group performance status of greater than 1, in-transit metastases, an autoimmune disease, uncontrolled infection, used systemic glucocorticoids or received previous systemic treatment for melanoma. Assignment was by 1:1 randomisation to groups receiving either 200 mg of adjuvant pembrolizumab (N = 514) or placebo (N = 505) every three weeks for one year or until recurrence, unacceptable toxicity, protocol violation or withdrawal. Follow-up was by clinical review with computed tomography and/or magnetic resonance imaging every 12 weeks for the

initial 2 years, then every 6 months until the end of year 5 and annually thereafter. For the present study, clinical cut-off date was 30th September 2019.

This study obtained ethical approval from the EORTC protocol-review committee and was conducted in compliance with the Declaration of Helsinki. All patients in the 1325 trial provided written informed consent.

2.2. β -blocker use

The use of β -blockers was defined as oral administration of any β -blocker between the date of randomization and 30 days thereafter. Both β 1-selective agents (e.g. acebutolol, atenolol, betaxolol, bisoprolol, celiprolol, esmolol, metoprolol and nebivolol) and non-selective agents (e.g. carteolol, carvedilol, labetalol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, practolol, propranolol, sotalol and timolol) were included. The use of topical β -blockers at baseline was defined using the same time window as for oral β -blockers. Patients who received them were not included in the main analyses as described subsequently.

2.3. Outcomes

As previously published [9, 10], the primary end-point was recurrence-free survival (RFS). RFS was defined as the time between the date of randomization and the date of recurrence (local, regional, distant metastasis) or death (whatever the cause), whichever occurred first. The date of recurrence was assumed to be the date of clinical assessment when recurrence was first detected. For patients who remained alive and without recurrence, RFS was censored at the most recent date of clinical assessment.

2.4. Statistical analysis

RFS was estimated using the Kaplan–Meier estimator and confidence intervals using the normal approximation of the distribution of $\log(-\log(\text{survival}))$ and the Greenwood variance formula. Univariable and multivariable Cox models were used to estimate hazard ratios (HRs) and 95% confidence interval (95% CI) for the associations between baseline oral β -blocker use and RFS. The multivariable Cox model included adjustments for treatment arm, disease stage (stage IIIA versus stage IIIB versus stage IIIC with 1–3 positive nodes versus stage IIIC with >3 positive nodes), age (<50 vs 50–<65 vs \geq 65 years), sex and BMI (<25 vs 25–<30 vs \geq 30 kg/m²). The predictive value of oral β -blocker use for RFS was estimated by adding a further

term to the aforementioned Cox model for the interaction between β -blockers and treatment arm.

In order to avoid potential bias due to topically administered β -blockers, a sensitivity analysis was performed by excluding patients that were using topical β -blockers from the group not using oral β -blockers. Finally, RFS according to use of β 1-selective and non-selective β -blockers separately was estimated using the Kaplan–Meier estimator, as described previously.

For all estimated parameters, point estimates and 95% confidence intervals were used. The proportional hazards assumption was verified using the approach by Lin, Wei and Ying [14] based on martingale residuals. All tests were performed at a two-sided significance level of 0.05. SAS software (SAS Institute) was used for all analyses.

3. Results

There were 1019 patients randomised to either pembrolizumab (n = 514) or placebo (n = 505) treatment arms. Baseline clinical characteristics are presented in Table 1. The majority had higher stage disease - stage IIIA (n = 152), IIIB (n = 472) or IIIC (n = 395). Ninety-nine (10%) patients were using oral β -blockers at baseline. Among the 920 patients not using oral β -blockers, eight patients (<1%) used topical β -blockers. The median follow-up was 37 months, and the inter-quartile range was 35–40 months.

Patients using oral β -blockers were older (41.4% versus 22.8% aged ≥ 65 years), had more advanced melanoma (46.4% versus 37.9% were stage IIIc) and had more comorbidities, including obesity (34.3% versus

Table 1
Baseline characteristics of patients according to oral β -blocker use at baseline.

	Oral β -blockers at baseline		Total (N = 1019) N (%)
	No (N = 920) N (%)	Yes (N = 99) N (%)	
Treatment arm			
Pembrolizumab	466 (50.7)	48 (48.5)	514 (50.4)
Placebo	454 (49.3)	51 (51.5)	505 (49.6)
Age (years)			
<50	368 (40.0)	11 (11.1)	379 (37.2)
50–64	342 (37.2)	47 (47.5)	389 (38.2)
65+	210 (22.8)	41 (41.4)	251 (24.6)
Sex			
Male	566 (61.5)	62 (62.6)	628 (61.6)
Female	354 (38.5)	37 (37.4)	391 (38.4)
ECOG PS			
0	869 (94.5)	91 (91.9)	960 (94.2)
1	51 (5.5)	8 (8.1)	59 (5.8)
AJCC-7 stage at baseline			
III A	137 (14.9)	15 (15.2)	152 (14.9)
III B	434 (47.2)	38 (38.4)	472 (46.3)
III C (1–3 LN+)	161 (17.5)	22 (22.2)	183 (18.0)
III C (>3 LN+)	188 (20.4)	24 (24.2)	212 (20.8)
BMI			
<25	321 (34.9)	18 (18.2)	339 (33.3)
25–<30	372 (40.4)	46 (46.5)	418 (41.0)
≥ 30	212 (23.0)	34 (34.3)	246 (24.1)
Missing	15 (1.6)	1 (1.0)	16 (1.6)
β-blocker use prior to baseline			
No reported	918 (99.8)	0 (0.0)	918 (90.1)
Less than 1 year	1 (0.1)	22 (22.2)	23 (2.3)
1–<2 years	0 (0.0)	9 (9.1)	9 (0.9)
2+ years	0 (0.0)	57 (57.6)	57 (5.6)
Reported, duration unknown	1 (0.1)	11 (11.1)	12 (1.2)
Oral selective β-blockers at baseline			
No	920 (100.0)	19 (19.2)	939 (92.1)
Yes	0 (0.0)	80 (80.8)	80 (7.9)
Oral non-selective β-blockers at baseline			
No	920 (100.0)	80 (80.8)	1000 (98.1)
Yes	0 (0.0)	19 (19.2)	19 (1.9)
β-blockers eye drops at baseline			
No	912 (99.1)	93 (93.9)	1005 (98.6)
Yes	8 (0.9)	6 (6.1)	14 (1.4)

Abbreviations: N (number), ECOG (Eastern Cooperative Oncology Group), PS (performance status), AJCC-7 (American Joint Committee on Cancer), BMI (body mass index).




Fig. 1. Recurrence-free survival by the use of oral β -blockers at baseline.

23.0% BMI ≥ 30 kg/m²), diabetes mellitus (24.2% versus 5.8%) and hypertension (85.9% versus 27.7%). [Supplementary Table 1](#) shows the distribution of comorbidities according to oral β -blocker use. [Supplementary Tables 2 and 3](#) show the baseline characteristics of patients according to both oral β -blocker use and treatment arm.

As previously published, there were 473 RFS events during follow-up, including newly diagnosed distant metastases ($n = 307$), locoregional recurrence only ($n = 160$), death ($n = 5$) or unknown type ($n = 1$). Pembrolizumab ($n = 190$ RFS events) compared with placebo ($n = 283$ RFS events) resulted in prolonged RFS: 3-year RFS rate, 63.7% versus 44.1% for pembrolizumab versus placebo, respectively; HR, 0.56; 95% CI, 0.47 to 0.68 [10].

Patients using oral β -blockers (in both arms combined) had a similar RFS compared to those not using β -blockers: the 3-year RFS rates were 54.0% (95% CI 43.6–63.3%) and 53.9% (95% CI: 50.6–57.1%), respectively, and the HR was 1.02 (95% CI 0.75–1.38) ([Fig. 1](#)). In addition, Cox multivariable analysis indicated that the use of β -blockers had no prognostic importance (RFS HR 0.96, 95% CI 0.70–1.31) when adjusting for treatment arm and possible confounding factors ([Table 2](#)). Pembrolizumab, a lower disease stage and a BMI between 25 and 30 kg/m² were significantly associated with a longer RFS whereas age and sex were not.

[Fig. 2](#) shows estimated RFS by treatment arm and β -blocker use. In a Cox multivariable analysis, the HR for the association between baseline oral β -blocker use and RFS was 0.67 (95% CI 0.38–1.19) in the pembrolizumab arm and 1.15 (95% CI 0.80–1.66) in the placebo arm ([Table 3](#)). The p -value for the interaction between treatment arms and β -blockers was 0.12.

Conversely, the HR for pembrolizumab compared to placebo comparison regarding RFS was 0.34 (95% CI 0.18–0.65) among patients using β -blockers and 0.59 (95% CI 0.48–0.71) among patients not using β -blockers. The difference between these two estimates was not statistically significant.

Excluding eight patients not using oral β -blockers at baseline that were using topical β -blockers made little difference to the association between oral β -blocker use and RFS among all patients (data not shown).

Among 99 patients using oral β -blockers at baseline, 80 were using β 1-selective β -blockers, while 19 only were using non-selective β -blockers. A Kaplan–Meier plot of RFS according to oral β -blocker subclass is shown in [Fig. 3](#). The 3-year RFS rates were 50.7% (95% CI: 39.3%–61.1%) and 66.9% (95% CI: 40.5–83.6%) for patients using β 1-selective and nonselective β -blockers, respectively. [Fig. 4](#) shows the Kaplan–Meier plot of RFS according to both oral β -blocker classes and treatment arm. In the pembrolizumab group, the 3-year RFS rates were 76.1% (95% CI: 59.0%–86.8%) and 65.6% (95% CI: 26.0%–87.6%) for patients using β 1-selective and non-selective β -blockers, respectively, and 28.6% (95% CI: 16.0%–42.5%) and 66.7% (95% CI: 28.2%–87.8%), respectively, in the placebo group.

4. Discussion

This study estimated the prognostic and predictive value of oral β -blockers on RFS in the EORTC 1325 clinical trial, which compared pembrolizumab to placebo among 1019 patients age 18 years or older, with biopsy confirmed high-risk stage IIIA (minimum sentinel node tumour deposit >1 mm), IIIB or IIIC melanoma and complete regional lymphadenectomy within 13 weeks

Table 2

Adjusted association of oral β -blocker use and baseline covariates with recurrence-free survival, estimated using a multivariable Cox model.

Parameter	Levels	Hazard Ratio (95% CI)	P-value
Oral β -blockers at baseline	No	1.00	0.793
	Yes	0.96 (0.70, 1.31)	
Treatment arm	Placebo	1.00	<0.001
	Pembrolizumab	0.56 (0.46, 0.67)	
AJCC-7 stage at baseline	III A	1.00	<0.001
	III B	1.90 (1.36, 2.65)	
	III C (1–3 LN+)	2.39 (1.66, 3.44)	
	III C (>3 LN+)	3.17 (2.24, 4.51)	
Sex	Male	1.00	0.069
	Female	0.84 (0.69, 1.01)	
Age (years)	<50	1.00	0.552
	50–64	1.04 (0.84, 1.29)	
	65+	1.14 (0.90, 1.45)	
BMI	<25	1.00	0.019
	25–<30	0.75 (0.60, 0.94)	
	≥ 30	0.98 (0.77, 1.24)	

Abbreviations: AJCC-7 (American Joint Committee on Cancer), BMI (body mass index). There was no evidence of non-proportional hazards for any of the covariates ($p > 0.05$).




Fig. 2. Recurrence-free survival by the use of oral β -blockers at baseline and treatment arm. Abbreviations: Pemb (pembrolizumab), Plac (placebo), BB (β -blockers).

prior to starting treatment. To our knowledge, this is the first study to estimate the prognostic and predictive value of β -blockers within a large, randomised controlled trial for adjuvant immunotherapy in melanoma.

Oral β -blockers did not confer a prognostic effect on RFS in either the unadjusted (HR 1.02) or adjusted analysis (HR 0.96). Interestingly, in a Cox multivariable

model, which considered the β -blocker–treatment interaction, patients using oral β -blockers had a larger improvement in RFS in the pembrolizumab arm (HR 0.67) than the placebo arm (HR 1.15). However, the differential prognostic importance of β -blockers in the two treatment arms did not reach statistical significance ($P = 0.12$). Conversely, patients using β -blockers had a larger treatment benefit from pembrolizumab

Table 3

Adjusted associations between β -blockers at baseline and recurrence-free survival by treatment arm, estimated using a multivariable Cox model.^a

Group	HR (95% CI)	P-value for the interaction
All patients	0.96 (0.70–1.31)	0.112
Treatment arm: Pembrolizumab	0.67 (0.38–1.19)	
Treatment arm: Placebo	1.15 (0.80–1.66)	

Abbreviations: HR (hazard ratio).

^a Cf model indicated in Table 3, where an interaction term, treatment group x β -blockers use, was added.

(HR = 0.34) than patients not using β -blockers (HR = 0.59), although the difference was not significant.

The observed benefit of β -blockers in patients receiving pembrolizumab supports the hypothesis of a role of β -adrenergic signalling in the inhibition of T cell activity, which in part mediates the action of pembrolizumab [15, 16]. β_2 signalling is thought to play the most important role (i.e. compared to β_1 and β_3) [13].

A number of other studies have investigated associations between β -blocker use and outcomes in melanoma. However, unlike the present work, most previous studies have been population-based studies (i.e. outside of a clinical trial) involving melanoma identified from health care records of various stages and unspecified treatments. In one such study involving 4,179 cases of stages I-IV melanoma in a Danish cancer register, Lemeshow *et al.* [17] found that use of β -blockers within 90 days of diagnosis was associated with prolonged overall survival (HR 0.81, 95% CI 0.67–0.97) and melanoma-specific survival (HR 0.87, 95% CI

0.64–1.20). In a similar study, involving 121 patients with Breslow thickness >1 mm melanoma, De Giorgi *et al.* [6] found that β -blockers were also significantly associated with overall survival (HR 0.62, 95% CI 43–90). Other population-based studies have only reported weak associations between β -blocker use and survival [18–20]. In addition, a small off-label study has investigated the effect of 80 mg of propranolol daily (taken from the time of diagnosis) on adverse outcomes among 19 of 53 patients with histologically confirmed stage IB to IIIA cutaneous melanoma and no evidence of metastasis [21]. In that study, patients receiving propranolol had markedly reduced risk of recurrence compared to those not receiving propranolol (adjusted HR 0.18, 95% CI, 0.04–0.89).

Only one published clinical study has investigated the effect of β -blockers on the efficacy of immunotherapy treatment in metastatic melanoma. Kokolus *et al.* [13] reported the results of a retrospective study involving a cohort of 195 patients with advanced melanoma who received different immunotherapy agents: IL-2, anti-CTLA-4 and/or anti-PD-1. They found that patients (N = 17) who used non-selective β -blockers had longer overall survival (numerical estimates were not reported) than those who received selective β -blockers (N = 45) or no β -blockers (N = 133). Therefore, there was consistency with our findings regarding non-selective β -blockers but not selective β -blockers. There is an ongoing early phase Ib/II trial investigating the effects of propranolol hydrochloride, a nonselective β -blocker, when given with pembrolizumab to patients with stage IIIC-IV melanoma that is not surgically resectable (NCT03384836).




Fig. 3. Recurrence-free survival by oral β_1 -selective and non-selective β -blocker use at baseline. Abbreviations: BB (β -blockers).




Fig. 4. Recurrence-free survival by oral β 1-selective and non-selective β -blocker use at baseline and treatment arm. Abbreviations: Pemb (pembrolizumab), Plac (placebo), BB (β -blockers), sel (selective).

The present study has a number of strengths, including a well-characterised cohort of patients with radiologically and biopsy proven resected stage III melanoma, a large sample size, prospective design and rigorous standards of data collection and follow-up of patients in this registration study. It is the first study, to our knowledge, to report quantitative estimates for the effects of β -blockers in melanoma treated with pembrolizumab. This makes the present study more relevant to current practice than the previous studies mentioned above.

There were also some limitations. First, the study’s observational design did not allow one to infer causation of the associations between β -blocker use and clinical outcomes. Second, there were some important differences in the distribution of comorbidities at baseline. Patients using β -blockers were more exposed to chronic health conditions, which are associated with increased mortality. This imbalance may have reduced the chance of observing a statistically significant association between β -blocker use and RFS, although death only accounted for 0.5% of RFS events. While the analyses adjusted for sex, age, BMI and stage, baseline comorbidities were not adjusted for due to a strong collinearity with β -blockers. Moderately increased BMI in this study was associated with increased survival similar to a previous report [22]. However, our analyses

did not explore possible interactions between BMI, sex and pembrolizumab treatment. A number of previous studies suggest that the pro-inflammatory phenotype of high BMI, particularly in males, influences immunotherapy efficacy [23, 24], although other studies have found no effect [25]. Third, there may have been misclassification of exposure to β -blockers if patients started to use β -blockers after the 30-day window used to define baseline exposure. For example, β -blockers may have been used for hyperthyroidism, which is a complication of pembrolizumab treatment. Conversely, other patients may have started to use β -blockers during the window but stopped shortly thereafter. The misclassification of β -blocker use would have reduced the chance of observing a statistically significant association between β -blockers and RFS. Finally, the numbers of patients were too small to better explore (e.g. uni- and multi-variable statistical analysis) the effects on RFS of different β -blocker subclasses (i.e. β 1-selective and nonselective) overall and in each treatment group. For the same reasons, the effect of β -blockers on different types of recurrences (e.g. diagnosed distant metastases, locoregional recurrence and so on) was not assessed.

In conclusion, this study investigated the prognostic and predictive value of oral β -blockers in a cohort of

patients with resected high-risk stage III melanoma treated with pembrolizumab or placebo. β -blockers did not appear to confer a prognostic effect on RFS. However, the analysis of the predictive value raised the possibility of increased efficacy of pembrolizumab among patients receiving β -blockers. The potential benefits of β -blockers when combined with immunotherapy in melanoma merit further investigation, including the study of the influence of β -blocker selectivity, other commonly used immunotherapy agents and the potential impact in the metastatic setting.

Author contributions

Oliver John Kennedy: Conceptualization, Methodology, Writing-original draft preparation, Writing-review and editing.

Sara Valpione, Sara Gandini: Conceptualization, Methodology, Writing-original draft preparation, Writing-review and editing.

Michal Kicinski: Conceptualization, Methodology, Data Curation, Formal analysis, Visualization, Writing-original draft preparation, Writing-review and editing.

Stefan Suci: Methodology, Writing-original draft preparation, Writing-review and editing.

Christian U. Blank, Georgina V. Long, Victoria G. Atkinson, Stéphane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J.M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Caroline Robert: Resources (patients), Investigation, Writing-review and editing.

Alexander MM Eggermont: Supervision, Writing-review and editing.

Paul Lorigan: Methodology, Resources (patients), Investigation, Supervision, Writing-original draft preparation, Writing-review and editing.

Mario Mandala: Conceptualization, Methodology, Resources (patients), Investigation, Supervision, Writing-original draft preparation, Writing-review and editing.

Data sharing statement

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD) is committed to providing qualified scientific researchers access to anonymized data and clinical study reports from the company's clinical trials for the purpose of conducting legitimate scientific research. MSD is also obligated to protect the rights and privacy of trial participants and, as such, has a procedure in place for evaluating and

fulfilling requests for sharing company clinical trial data with qualified external scientific researchers. The MSD data sharing website (available at: http://engagezone.msd.com/ds_documentation.php) outlines the process and requirements for submitting a data request. Applications will be promptly assessed for completeness and policy compliance. Feasible requests will be reviewed by a committee of MSD subject matter experts to assess the scientific validity of the request and the qualifications of the requestors. In line with data privacy legislation, submitters of approved requests must enter into a standard data-sharing agreement with MSD before data access is granted. Data will be made available for request after product approval in the US and EU or after product development is discontinued. There are circumstances that may prevent MSD from sharing requested data, including country or region-specific regulations. If the request is declined, it will be communicated to the investigator. Access to genetic or exploratory biomarker data requires a detailed, hypothesis-driven statistical analysis plan that is collaboratively developed by the requestor and MSD subject matter experts; after approval of the statistical analysis plan and execution of a data-sharing agreement, MSD will either perform the proposed analyses and share the results with the requestor or will construct biomarker covariates and add them to a file with clinical data that is uploaded to an analysis portal so that the requestor can perform the proposed analyses.

Funding

The EORTC1325/KEYNOTE-054 phase III trial work was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. The grant ID was MK 3475-054. For the study herein reported, no specific funding was received. SV was supported by a Harry J Lloyd Career Development Award.

Conflict of interest statement

Alexander Eggermont

Consulting fees: Agenus, Biocad, BioInvent, BioNTech, BMS, CatalYm, Ellipses, Galecto, GSK, IO Biotech, ISA Pharmaceuticals, Merck/MSD, Nektar, Novartis, Pfizer, SAiRoPA, Sellas, SkylineDx, TigeTx, TTxDiscovery.

Payment or honoraria: Biocad, BMS, Merck/MSD.

Participation on a Data Safety Monitoring Board or Advisory Board: GSK, Novartis and Pfizer.

Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: European Academy Cancer Sciences German Cancer Aid.

Stock or stock options: SkylineDx and SAiRoPA.

Rutger Koornstra

Grants or contracts from any entity: Roche.

Leonel Hernandez-Aya

Grants or contracts from any entity: Bristol Myers Squibb, Regeneron Pharmaceuticals, Immunocore, Merck, Polynoma, Corvus Pharmaceuticals, Roche, Genentech, Merck Serono, Amgen, MedImmune, Takeda Pharmaceuticals, Moderna Therapeutics.

Consulting fees: Massive Bio, Bristol Myers Squibb - Advisory Board.

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Sanofi, Regeneron Pharmaceuticals - Speakers bureau.

Support for attending meetings and/or travel: Sanofi, Regeneron Pharmaceuticals, Bristol Myers Squibb.

Anna Maria di Giacomo

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: BMS, MSD, Pierre Fabre, Sanofi.

Support for attending meetings and/or travel: BMS, Pierre Fabre.

Participation on a Data Safety Monitoring Board or Advisory Board: BMS, MSD, Nektar, Pierre Fabre, Sanofi, GSK, Novartis.

Alfonsus J.M. van den Eertwegh

Grants or contracts from any entity: Roche, Sanofi, Bristol Myers Squibb.

Consulting fees: Bristol Myers Squibb.

Support for attending meetings and/or travel: MSD Oncology, Roche, Pfizer, Sanofi.

Participation on a Data Safety Monitoring Board or Advisory Board: Bristol Myers Squibb, MSD Oncology, Amgen, Roche, Novartis, Sanofi, Pfizer, Ipsen, Merck, Pierre Fabre.

Jean-Jacques Grob

Consulting fees: Bristol Myers Squibb, MSD Oncology, Roche/Genentech, Novartis, Amgen, Pierre Fabre, Sun Pharma, Merck KGaA, Sanofi, Pfizer, Roche.

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Novartis - Speakers bureau.

Support for attending meetings and/or travel: BMS, MSD Oncology, Novartis, Pierre Fabre.

Ralf Gutzmer

Grants or contracts from any entity: Pfizer, Novartis, Johnson & Johnson, Amgen, Merck Serono, Sun Pharma Industries, Sanofi.

Consulting fees: Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Genentech, Novartis, Merck Serono, Almirall, Amgen, Sun Pharma Industries, Pierre Fabre, Sanofi, Regeneron Pharmaceuticals, Bayer AG, Immunocore.

Support for attending meetings and/or travel: Bristol Myers Squibb, Roche, Merck Serono, Pierre Fabre, Sun Pharma Industries.

Rahima Jamal

Grants or contracts from any entity: Merck Sharp & Dohme, Bristol Myers Squibb.

Caroline Robert

Consulting fees: ROCHE, NOVARTIS, PIERRE FABRE, MSD, BMS, SANOFI, PFIZER, AstraZeneca.

Oliver John Kennedy

None declared.

Paul Lorigan

Grants or contracts from any entity: BMS, Pierre Fabre.

Consulting fees: BMS, Merck, GSK.

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Pierre Fabre, Novartis, MSD, BMS.

Support for attending meetings and/or travel: BMS, Support to attend ASCO, MSD - Support to attend ASCO.

Mario Mandalà

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: BMS, MSD, NOVARTIS, PIERRE FABRE, SANOFI.

Participation on a Data.

Safety Monitoring Board or Advisory Board: Bristol Myers Squibb, MSD Oncology, Novartis, Pierre Fabre - Advisory Boards.

Michal Kicinski

All support for the present manuscript: Merck - Merck is the sponsor of the study (money paid to my institution).

Grants or contracts from any entity: Pierre Fabre - Sponsor and provider of an academic grant for different melanoma studies (money paid to my institution), BMS - Sponsor and provider of an academic grant for different melanoma studies (money paid to my institution).

Stefan Suciu

All support for the present manuscript: Merck - Merck is the sponsor of the study (money paid to my institution).

Grants or contracts from any entity: BMS, Pierre-Fabre - Sponsor and provider of academic grants to other EORTC melanoma studies; payments were made to my institution.

Sara Valpione

None declared.

Sara Gandini

None declared.

Christian Blank

Grants or contracts from any entity: BMS, Novartis, NanoString, and 4SC.

Consulting fees: BMS, MSD, Roche, Novartis, Lilly, Pfizer, GSK, GenMab and Pierre Fabre - Payments were made to my institution, Third Rock Venture - Payments were made to me.

Stock or stock options: Unity Cars – Stocks, Immagine BV – Co-founder.

Alexander C.J. van Akkooi

Grants or contracts from any entity: Amgen, Merck-Pfizer.

Participation on a Data Safety Monitoring Board or Advisory Board: Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Sirius Medical, 4SC.

Georgina V Long

Consulting fees: GVL is consultant advisor for Aduro Biotech Inc, Amgen Inc, Array Biopharma inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Hexel AG, Highlight Therapeutics S.L., Merck Sharpe & Dohme, Novartis Pharma AG, OncoSec, Pierre Fabre, QBiotech Group Limited, Regeneron Pharmaceuticals Inc, Specialised Therapeutics Australia Pty Ltd.

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Bristol Myers Squibb - Personal 1 h lecture of my own slides, Pierre Fabre, Personal 1 h lecture of my own slides.

Participation on a Data: Safety Monitoring Board or Advisory Board: See consulting fees, All for advisory boards.

Victoria Atkinson

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Bristol Myers Squibb, MSD, Nektar, Novartis, Pierre Fabre, Q Biotics, Roche, Limbic - Advisory boards, Bristol Myers Squibb, MSD, Novartis, Pierre Fabre- Speakers bureaus fees.

Support for attending meetings and/or travel: BMS, Travel support.

Participation on a Data Safety Monitoring Board or Advisory Board: Bristol Myers Squibb, MSD, Nektar, Novartis, Pierre Fabre, Q Biotics, Roche, Limbic - Advisory boards.

Stephane Dalle

Grants or contracts from any entity: Bristol Myers Squibb, Merck Sharp & Dohme - My Institution.

Support for attending meetings and/or travel: Bristol Myers Squibb, Pierre Fabre, Merck Sharp & Dohme.

Other financial or non-financial interests: Sanofi Pasteur - My wife is an employee of Sanofi Pasteur.

Andrew M. Haydon

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Novartis, Merck - Honoraria for lectures, presentations, speakers bureaus.

Participation on a Data Safety Monitoring Board or Advisory Board: Novartis, Pierre Fabre, Merck Sharp & Dohme - Advisory Boards.

Andrey Meshcheryakov

Grants or contracts from any entity: Sanofi, AstraZeneca, Merck Sharp & Dohme - My institution, me.

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Amgen, Bayer AG, BIOCAD, Bristol Myers Squibb, Eli Lilly, Merck, SERVIER, Takeda Pharmaceuticals, Eisai, AstraZeneca, Sanofi-Aventis - Honoraria for lectures, presentations, speakers bureaus.

Support for attending meetings and/or travel: BIOCAD, SERVIER, Merck Sharp & Dohme, Sanofi-Aventis, Merck - Attending meetings and/or travel.

Participation on a Data Safety Monitoring Board or Advisory Board: Amgen, Bayer AG, BIOCAD, Bristol Myers Squibb, Eli Lilly, Merck, SERVIER, Takeda Pharmaceuticals, Eisai, AstraZeneca, Sanofi-Aventis - Advisory Board.

Adnan Khattak

None declared.

Matteo S. Carlino

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Bristol Myers Squibb, MSD, Novartis - Honoraria for lectures, presentations, speakers bureaus.

Participation on a Data Safety Monitoring Board or Advisory Board: Bristol Myers Squibb, MSD, Amgen, Novartis, Pierre Fabre, Roche, IDEAYA Biosciences, Sanofi, Merck Serono, Regeneron Pharmaceuticals, QBiotech, Nektar, Eisai - Advisory Board.

Shahneen Sandhu

Grants or contracts from any entity: Advanced Accelerators Applications (a Novartis company), Amgen, Merck Sharp & Dohme, Merck Serono, Genentech, AstraZeneca - Funding to the institution.

Consulting fees: Amgen, Merck Sharp & Dohme, Merck Serono, AstraZeneca, Bristol Myer Squibb - Funding to the institution.

James Larkin

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Eisai, Novartis, Incyte, Merck, touchIME, touchEXPERTS, Pfizer, Royal College of Physicians, Cambridge Healthcare research, Royal College of General Practitioners, VJ Oncology, Agence Unik, Bristol Myers Squibb - Honoraria for lectures, presentations.

Participation on a Data Safety Monitoring Board or Advisory Board: Pierre Fabre, BMS, Ipsen, Roche, EUSA Pharma, Novartis, Aptitude, AstraZeneca, GSK, Eisai, Calithera, Ultimovacs, Seagen, Merck, eCancer, MCA, Inselgruppe, Pfizer, Goldman Sachs, MSD - Advisory Board.

Susana Puig

Grants or contracts from any entity: Almirall - To My Institution, ISDIN - To My Institution, La Roche Posay - To My Institution.

Consulting fees: ISDIN, Almirall, La Roche Posay - To Me, Sanofi, Sunpharma - To Me, Pfizer, Roche, Regeneron - To Me.

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: ISDIN, La Roche Posay - To Me, Pfizer, Roche, Regeneron - To Me, BMS, Sunpharma - TO ME.

Support for attending meetings and/or travel: Almirall - TO ME.

Participation on a Data Safety Monitoring Board or Advisory Board: Roche, Sanofi - To Me, Sunpharma, Almirall - To Me, ISDIN, Pfizer, Novartis - TO ME.

Paolo A. Ascierto

Grants or contracts from any entity: Bristol Myers Squibb, Roche, Genentech, Array BioPharma - To my institution.

Consulting fees: Bristol Myers Squibb, Roche, Genentech, Merck Sharp & Dohme, Novartis, Array BioPharma, Merck Serono, Pierre Fabre, Incyte, MedImmune, AstraZeneca, Sun Pharma Industries, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer Ingelheim, Eisai, Regeneron Pharmaceuticals - To me.

Participation on a Data Safety Monitoring Board or Advisory Board: Bristol Myers Squibb, Roche, Genentech, Merck - Advisory Board.

Sharp & Dohme, Novartis, Array BioPharma, Merck Serono, Pierre Fabre, Incyte, MedImmune, AstraZeneca, Sun Pharma Industries, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer Ingelheim, Eisai, Regeneron Pharmaceuticals - To me.

Piotr Rutkowski

Grants or contracts from any entity: Novartis, Roche, Bristol Myers Squibb - My institution.

Consulting fees: Bristol Myers Squibb, MSD, Novartis, Roche, Eli Lilly, Pfizer, Pierre.

Fabre - Advisory Role - Personal fees.

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Novartis, Blueprint Medicines, Bristol Myers Squibb, Pierre Fabre, MSD, Amgen - Advisory boards, To me, Pfizer, Novartis, Eli Lilly - speakers bureaus.

Participation on a Data Safety Monitoring Board or Advisory Board: See above - Advisory Board.

Dirk Schadendorf

Grants or contracts from any entit: Bristol Myers Squibb, Novartis, Roche, MSD Oncology, Array BioPharma/Pfizer.

Consulting fees: Roche/Genentech, Novartis, Bristol Myers Squibb, Merck Sharp & Dohme, Immunocore, Merck Serono, Array BioPharma, Pfizer, Pierre Fabre, Philogen, Regeneron, 4SC, Sanofi/Regeneron, NeraCare GmbH, Sun Pharma, Inflarx GmbH, Ultimovacs, Sandoz.

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Sanofi/Regeneron, Merck KGaA - speakers bureaus.

Support for attending meetings and/or travel: Roche/Genentech, Bristol Myers Squibb, Merck Serono, Novartis, Merck Sharp & Dohme, Pierre Fabre, Sanofi/Regeneron.

Participation on a Data Safety Monitoring Board or Advisory Board: Roche/Genentech, Novartis, Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, 4SC, Pierre Fabre, Sanofi/Regeneron, Nektar - Advisory Board.

Acknowledgements

The authors are grateful to Merck & Co., Inc., Kenilworth, NJ, USA for supporting the independent EORTC study EORTC1325/KEYNOTE-054. We thank all the investigators who participated to this study, who have not been included among the co-author list of this publication (Supplementary List A1). The authors warmly thank all EORTC Headquarters team members who have not been included among the co-author list of this publication, and who contributed to the study success (S. Marreaud, S. Janssen, R. Louis, N. Elaut, L. Wijnen, N. Jha, S Rivrain and G. de Schaetzen) as well as Merck & Co., Inc., Kenilworth, NJ, USA team members (C. Krepler, N. Ibrahim, V. Rivas, R. Kloss Silverman and S. Diede).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ejca.2022.01.017>.

Appendix

List A1

The list additional investigators participated in the EORTC 1325/KEYNOTE 054 trial, but their names were not included in the author list of this article.

Investigator name	Investigator site	City	Country
Alex Menzies	Melanoma Institute Australia, The University of Sydney, and Mater and Royal North Shore Hospitals	Sydney	Australia
Brown Michael	Royal Adelaide Hospital	Adelaide	Australia
Hersey Peter	David Maddison Clinical Sciences	Newcastle	Australia
Parente Phillip	Box Hill Hospital	Box Hill	Australia
Dzienis Marcin	Gold Coast University Hospital	Southport QLD	Australia
Mcneil Catriona	Chris O'Brien Lifehouse	Camperdown NSW	Australia
Hoeller Christoph	Medical University Vienna - General Hospital AKH	Vienna	Austria
Hofmann-Wellenhof Rainer	Medical University of Graz	Graz	Austria
Bechter Oliver	U.Z. Leuven - Campus Gasthuisberg	Leuven	Belgium
Baurain Jean-Francois	Cliniques Universitaires Saint-Luc	Brussels	Belgium
Kerger Joseph	Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet	Brussels	Belgium
Song Xinni	The Ottawa Hospital, The Integrated Cancer Program- General Campus	Ottawa	Canada
Walker John	Department of Oncology - University of Alberta - Cross Cancer Institute	Edmonton	Canada
Svane Inge Marie	Herlev Hospital - University Copenhagen	Herlev	Denmark
Bastholt Lars	Odense University Hospital	Odense	Denmark
Schmidt Henrik	Aarhus University Hospital	Aarhus	Denmark
Hernberg Micaela	Helsinki University Central Hospital - Dept of Oncology	Helsinki	Finland
Skytta Tanja	Tampere University Hospital	Tampere	Finland
Lesimple Thierry	Centre Eugene Marquis	Rennes	France
Mortier Laurent	CHRU de Lille	Lille	France
Dutriaux Caroline	CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre	Bordeaux	France
Guillot Bernard	Hopital St. Eloi	Montpellier	France
Grange Florent	CHU de Reims - Hôpital Robert Debré	Reims	France
Saiag Philippe	Assistance Publique - Hopitaux de Paris - CHU Ambroise Pare	Boulogne-Billancourt	France
Arnault Jean-Philippe	CHU Amiens - Hopital Sud	Salouel	France
Lebbe Celeste	Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis	Paris	France
Eve-Marie Neidhardt, Combemale Patrick	Centre Leon Berard	Lyon	France
Leccia Marie-Therese	CHU de Grenoble - La Tronche - Hôpital A. Michallon	Grenoble	France
Geoffrois Lionel	Institut de Cancérologie de Lorraine	Vandoeuvre-Les-Nancy	France
Machet Laurent	CHU de Tours - Hopital Trousseau	Tours	France
Descamps Vincent	Assitance Publique - Hopitaux de Paris - Hopital Bichat-Claude Bernard	Paris	France
Lacour Jean-Philippe	CHU de Nice - Hopital De L'Archet	Nice	France
Aubin Francois	CHRU de Besancon - Hopital Saint-Jacques	Besancon	France
Avril Marie-Francoise	Assistance Publique - Hopitaux de Paris - Hopital Cochin	Paris	France
Jouary Thomas	Centre Hospitalier De Pau	Pau	France
Meier Friedegund	Universitaetsklinikum Carl Gustav Carus	Dresden	Germany
Loquai Carmen	Johannes Gutenberg Universitaetskliniken - Mainz University Medical Center	Mainz	Germany
Garbe Claus	Eberhard Karls Universitaet - Hautklinik	Tuebingen	Germany
Mohr Peter	Krankenhaus Buxtehude	Buxtehude	Germany
Meiss Frank	Universitaetsklinikum Freiburg	Freiburg	Germany
Simon Jan-Christoph	Universitaetsklinikum Leipzig - Clinic for Dermatology, Venerology and Allergology	Leipzig	Germany

(continued on next page)

List A1 (continued)

Investigator name	Investigator site	City	Country
Hauschild Axel	Universitaetsklinikum Schleswig –Holstein - Campus Kiel-Klinik Dermatologie, Venerologie und Allergologie	Kiel	Germany
Kretschmer Lutz	Universitaetsmedizin Goettingen - Georg-August Universitaet	Goettingen	Germany
Hassel Jessica	Universitaetsklinikum Heidelberg - Hautklinik/Dermatologic Department	Heidelberg	Germany
Kiecker Felix	Charite - Universitaetsmedizin Berlin - Campus Mitte	Berlin	Germany
Berking Carola	Ludwig-Maximilians-Universitaet Muenchen - Klinik und Poliklinik für Dermatologie und Allergologie - Innenstadt	Muenchen	Germany
Utikal Jochen	UniversitaetsMedizin Mannheim	Mannheim	Germany
Hein Ruediger	Technische Universitaet Muenchen	Muenchen	Germany
Terheyden Patrick	Universitaetsklinikum Schleswig –Holstein - Campus Luebeck	Luebeck	Germany
Schachter Jacob	Sheba Medical Center	Ramat Gan	Israel
Bar Sela Gil	Rambam Health Care Campus, Oncology Institute	Haifa	Israel
Lotem Michal	Hadassah University Hospital	Jerusalem	Israel
Hendler Daniel	Rabin Medical Center - Tel Aviv University	Petah Tikva	Israel
Quaglino Pietro	Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale San Lazzaro	Torino	Italy
Queirolo Paola	Istituto Nazionale Per La Ricerca Sul Cancro	Genova	Italy
Chiarion-Sileni Vanna	Azienda Ospedaliera Di Padova	Padova	Italy
Ferrucci Pier Francesco	Istituto Europeo di Oncologia	Milano	Italy
Ferraresi Virginia	Regina Elena National Cancer Center	Roma	Italy
Yamazaki Naoya	National Cancer Center Hospital	Tokyo	Japan
Yokota Kenji	Nagoya University Hospital	Nagoya-shi	Japan
Inozume Takashi	Yamanashi University Hospital	Chuo-Shi	Japan
Kiyohara Yoshio	Shizuoka Cancer Center	Sunto-gun	Japan
Hironobu Ihn	Kumamoto University Hospital	Kumamoto	Japan
Takenouchi Tatsuya	Niigata Prefectural Cancer Center Hospital	Niigata-City	Japan
Hospers G.A.P.	University Medical Center Groningen	Groningen	Netherlands
Aarts M.J.B.	Academisch Ziekenhuis Maastricht	Maastricht	Netherlands
Groenewegen Gerard	Universitair Medisch Centrum - Academisch Ziekenhuis	Utrecht	Netherlands
Kapiteijn Ellen	Leiden University Medical Centre	Leiden	Netherlands
Barrow Catherine	Wellington Hospital	Wellington	New Zealand
Fitzharris Bernie	Christchurch Hospital	Christchurch	New Zealand
Fisher Rosalie	North Shore Hospital - Waitemata DHB	Takapuna	New Zealand
Jameson Michael Barrett	Waikato Hospital	Hamilton	New Zealand
Aamdal Steinar	Oslo University Hospital - Radiumhospitalet	Oslo	Norway
Straume Oddbjorn	Haukeland Hospital - University Of Bergen	Bergen	Norway
Mackiewicz Andrzej	The Great Poland Cancer Centre	Poznan	Poland
Passos Maria Jose	I.P.O. Francisco Gentil - Centro De Lisboa	Lisboa	Portugal
Ferreira Paula	Instituto Portugues De Oncologia - Centro Do Porto	Porto	Portugal
Martins Cesar	Hospital Distrital De Santarem	Santarem	Portugal
Stroyakovskiy Daniil	Municipal Oncology Hospital 62	Moscow	Russian Federation
Mukhametshina Guzel	Republic Clinical Oncology Dispensary of Ministry of Health of Tatarstan Republic	Kazan	Russian Federation
Kandolf-Sekulovic Lidija	Military Medical Academy	Belgrade	Serbia
Dzodic Radan, Suzana Matkovic	Institute Of Oncology & Radiology	Belgrade, Serbia	Serbia
Ortiz Romero Pablo Luis	Hospital Universitario 12 De Octubre	Madrid	Spain
Levin Max	Sahlgrenska Universitetssjukhuset	Goteborg	Sweden

List A1 (continued)

Investigator name	Investigator site	City	Country
Dummer Reinhard	UniversitaetsSpital Zurich	Zurich	Switzerland
Fehr Martin	Kantonsspital St Gallen	St Gallen	Switzerland
Rastine Merat	Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie	Geneve	Switzerland
Marples Maria	Leeds Teaching Hospitals NHS Trust - St. James's University Hospital	Leeds	United Kingdom
Corrie Philippa	Cambridge University Hospital NHS - Addenbrookes Hospital	Cambridge	United Kingdom
Waterston Ashita	NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital	Glasgow	United Kingdom
Casasola Richard	University Of Dundee - Ninewells Hospital	Dundee, Scotland	United Kingdom
Marshall Ernest	Clatterbridge Cancer Centre NHS Foundation Trust	Bebington, Wirral	United Kingdom
Yone You	Mid Essex Hospitals - Broomfield Hospital	Broomfield (essex)	United Kingdom
Nathan Paul	East and North Hertfordshire NHS Trust – Mount Vernon Hospital	Northwood	United Kingdom
Kudchadkar Ragini	Emory University	Atlanta	United States of America
Algazi Alain	UCSF University of California San Francisco Medical Center–Mount Zion	San Francisco	United States of America
Milhem Mohammed	University Of Iowa Hospital And Clinics	Iowa City	United States of America
Hallmeyer Sigrun	Lutheran General Hospital/Advocate Cancer Care Center	Park Ridge	United States of America
Kim Kevin	California Pacific Medical Center	San Francisco	United States of America

References

- Wang W, Cao X. Beta-adrenergic signaling in tumor immunology and immunotherapy. *Crit Rev Immunol* 2019;39:93–103. <https://doi.org/10.1615/CritRevImmunol.2019031188>.
- Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. *Clin Cancer Res* 2012;18:1201–6. <https://doi.org/10.1158/1078-0432.CCR-11-0641>.
- Moretti S, Massi D, Farini V, Baroni G, Parri M, Innocenti S, et al. β -adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. *Lab Invest* 2013;93:279–90. <https://doi.org/10.1038/labinvest.2012.175>.
- Rains SL, Amaya CN, Bryan BA. Beta-adrenergic receptors are expressed across diverse cancers. *Oncoscience* 2017;4:95–105. <https://doi.org/10.18632/oncoscience.357>.
- Yap A, Lopez-Olivo MA, Dubowitz J, Pratt G, Hiller J, Gottumukkala V, et al. Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies. *Br J Anaesth* 2018;121:45–57. <https://doi.org/10.1016/j.bja.2018.03.024>.
- De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N, et al. Treatment with β -blockers and reduced disease progression in patients with thick melanoma. *Arch Intern Med* 2011;171:779–81. <https://doi.org/10.1001/archinternmed.2011.131>.
- De Giorgi V, Gandini S, Grazzini M, Benemei S, Marchionni N, Geppetti P. Effect of β -blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. *Mayo Clin Proc* 2013;88:1196–203. <https://doi.org/10.1016/j.mayocp.2013.09.001>.
- Ugurel S, Röhm J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, et al. Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019. *Eur J Cancer* 2020;130:126–38. <https://doi.org/10.1016/j.ejca.2020.02.021>.
- Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. *N Engl J Med* 2018;378:1789–801. <https://doi.org/10.1056/NEJMoa1802357>.
- Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial. *J Clin Oncol* 2020;38:3925–36. <https://doi.org/10.1200/JCO.20.02110>.
- Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncol* 2021;22:643–54. [https://doi.org/10.1016/S1470-2045\(21\)00065-6](https://doi.org/10.1016/S1470-2045(21)00065-6).
- Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwiecki B, et al. β -Adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy. *Cancer Res* 2017;77:5639–51. <https://doi.org/10.1158/0008-5472.CAN-17-0546>.
- Kokolus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, Repasky EA, et al. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. *OncImmunology* 2018;7:e1405205. <https://doi.org/10.1080/2162402X.2017.1405205>.
- Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. *Biometrika* 1993;80:557–72. <https://doi.org/10.2307/2337177>.
- Maisel AS, Fowler P, Rearden A, Motulsky HJ, Michel MC. A new method for isolation of human lymphocyte subsets reveals differential regulation of beta-adrenergic receptors by terbutaline treatment. *Clin Pharmacol Ther* 1989;46:429–39. <https://doi.org/10.1038/clpt.1989.161>.

- [16] Sanders VM, Baker RA, Ramer-Quinn DS, Kasproicz DJ, Fuchs BA, Street NE. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. *J Immunol* 1997;158:4200–10.
- [17] Lemeshow S, Sørensen HT, Phillips G, Yang EV, Antonsen S, Riis AH, et al. β -Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. *Cancer Epidemiol Biomarkers Prev* 2011;20:2273–9. <https://doi.org/10.1158/1055-9965.EPI-11-0249>.
- [18] McCourt C, Coleman HG, Murray LJ, Cantwell MM, Dolan O, Powe DG, et al. Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study. *Br J Dermatol* 2014;170:930–8. <https://doi.org/10.1111/bjd.12894>.
- [19] Livingstone E, Hollestein LM, van Herk-Sukel MPP, van de Poll-Franse L, Nijsten T, Schadendorf D, et al. β -Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. *Eur J Cancer* 2013;49:3863–71. <https://doi.org/10.1016/j.ejca.2013.07.141>.
- [20] Katsarelias D, Eriksson H, Mikiver R, Krakowski I, Nilsson JA, Ny L, et al. The effect of beta-adrenergic blocking agents in cutaneous melanoma-A nation-wide Swedish population-based retrospective register study. *Cancers* 2020;12. <https://doi.org/10.3390/cancers12113228>.
- [21] De Giorgi V, Grazzini M, Benemei S, Marchionni N, Botteri E, Pennacchioli E, et al. Propranolol for off-label treatment of patients with melanoma: results from a cohort study. *JAMA Oncol* 2018;4:e172908. <https://doi.org/10.1001/jamaoncol.2017.2908>.
- [22] Hayes AJ, Larkin J. BMI and outcomes in melanoma: more evidence for the obesity paradox. *Lancet Oncol* 2018;19:269–70. [https://doi.org/10.1016/S1470-2045\(18\)30077-9](https://doi.org/10.1016/S1470-2045(18)30077-9).
- [23] Woodall MJ, Neumann S, Campbell K, Pattison ST, Young SL. The effects of obesity on anti-cancer immunity and cancer immunotherapy. *Cancers* 2020;12. <https://doi.org/10.3390/cancers12051230>.
- [24] McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. *Lancet Oncol* 2018;19:310–22. [https://doi.org/10.1016/S1470-2045\(18\)30078-0](https://doi.org/10.1016/S1470-2045(18)30078-0).
- [25] Rutkowski P, Indini A, De Luca M, Merelli B, Mariuk-Jarema A, Teterycz P, et al. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. *J Immunother Cancer* 2020;8. <https://doi.org/10.1136/jitc-2020-001117>.